Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May;19(3):234-40.
doi: 10.1097/CCO.0b013e3280ad4388.

Renal cell carcinoma

W Kimryn Rathmell  1 , Caroline A Martz, Brian I Rini
Affiliations
Review

Renal cell carcinoma

W Kimryn Rathmell et al. Curr Opin Oncol. 2007 May.

Abstract

Purpose of review: This review highlights recent contributions to the biology and treatment of renal cell carcinoma, the expanded use of antiangiogenic agents as well as interest in other inhibitory drug mechanisms. In addition, recent findings are reported on biomarkers which are undergoing investigation as correlative prognostic indicators of either survival or response to treatment.

Recent findings: Advances in our understanding of the molecular biology underpinning renal cell carcinoma and the introduction of new targeted therapeutics with benefit in the metastatic setting have had a major impact on the treatment of this disease.

Summary: The management of metastatic renal cell carcinoma has undergone a dramatic evolution in the past year, marked by the approval of two drugs by the US Food and Drug Administration. These drugs have demonstrated improved progression-free survival as well as potentially improved overall survival for patients with metastatic disease. These groundbreaking treatment strategies have fueled a surge in translational studies expanding our knowledge of the molecular biology of renal cell carcinoma.

PubMed Disclaimer

MeSH terms